GF Fund Management’s Pacira BioSciences PCRX Stock Holding History

GF Fund Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21.8K	Sell	860 -107	-11%	-$2.53K	﹤0.01%	477
2026 Q1	$21.9K	Buy	967 +123	+15%	+$2.73K	﹤0.01%	492
2025 Q4	$21.8K	Sell	844 -123	-13%	-$2.92K	﹤0.01%	498
2025 Q3	$24.9K	Sell	967 -215	-18%	-$5.28K	﹤0.01%	466
2025 Q2	$28.3K	Hold	1,182	–	–	﹤0.01%	465
2025 Q1	$29.4K	Buy	1,182 +212	+22%	+$5.08K	﹤0.01%	463
2024 Q4	$18.3K	Buy	+970	New	+$17K	﹤0.01%	480

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GF Fund Management's PCRX Position: Q2 2026 in Review

GF Fund Management reduced its Pacira BioSciences (PCRX) stake by 11% in Q2 2026, selling an estimated $2.53K and leaving 860 shares worth $21.8K. The position accounts for ﹤0.01% of the portfolio, ranked #477.

GF Fund Management first reported a position in PCRX in Q4 2024 and has held it in 7 quarters since. The position peaked at $29.4K in Q1 2025. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

GF Fund Management held 860 shares of Pacira BioSciences worth $21.8K as of Q2 2026.
GF Fund Management sold 107 Pacira BioSciences shares in Q2 2026, an estimated $2.53K.
Pacira BioSciences made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #477 holding.
GF Fund Management first reported a position in Pacira BioSciences in Q4 2024 and has held it in 7 quarters since.
GF Fund Management's Pacira BioSciences position peaked at $29.4K in Q1 2025.
254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.